HSD3B1 and Familial prostate cancer: The cumulative incidence of PCSM at 5 years after diagnosis of prostate cancer was higher among patients with the HSD3B1 CC genotype (4.0%; 95% CI, 1.7%-6.2%) compared with the AC genotype (2.1%; 95% CI, 1.3%-2.8%) and AA genotype (1.9%; 95% CI, 1.3%-2.4%) (P = .02) (Figure 1).